Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides (TECLA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by University of Cologne.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Prof. Dr. med. Dr. rer. nat Cornelia Mauch, University of Cologne
ClinicalTrials.gov Identifier:
NCT01645293
First received: July 11, 2012
Last updated: July 17, 2012
Last verified: July 2012

July 11, 2012
July 17, 2012
Not Provided
Not Provided
  • Rate of patients experiencing dose limiting toxicities of engineered T cells #1138. [ Designated as safety issue: Yes ]
  • Definition of maximum tolerated dose (MTD) of engineered T cells #1138. [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01645293 on ClinicalTrials.gov Archive Site
Preliminary evidence of response to treatment [ Designated as safety issue: No ]
  • Complete Response (CR): Disappearance of treated lesion.
  • Partial Response (PR): At least 30% decrease in the sum of two diameters compared to the initiatal diameters of the treated lesion.
  • Progressive Disease (PD): At least 20% increase in the sum of two diameters of treated lesions.
  • Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of two diameters while on study.
Same as current
Not Provided
Not Provided
 
Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides
Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides

Patients with cutaneous CD30 positive lymphoma will receive systemical and topical treatment with their own genetically modified T cells. Treatment evaluation consists of assessment of safety and preliminary evidence of response.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • CD30 Positive Cutaneous T Cell Lymphoma
  • CD30 Positive Transformed Mycosis Fungoides
Genetic: Genetically modified T cells # 1138
Experimental: Genetically modified T cells #1138
Intervention: Genetic: Genetically modified T cells # 1138
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
15
Not Provided
Not Provided

Inclusion Criteria:

  • Signed written informed consent, prior to pre-study screening and treatment, with the understanding that the consent may be withdrawn by the patient at any time without prejudice, ability to understand the written informed consent document.
  • Male or female > 18 years of age to 70 years of age
  • Diagnosis of primary cutaneous CD30+ large T cell lymphoma OR
  • Diagnosis of transformed CD30+ mycosis fungoides, i.e.,
  • Histological confirmation of diagnosis.
  • multiple (> 5) cutaneous tumor lesions (TNM EORTC 2007 T3, N1, clinical stage <IIb),
  • Measurable disease according to RECIST criteria
  • Refractory or relapsed disease after at least one line of treatment, e.g. PUVA (Psoralen plus UVA), PUVA + Interferon, oral Bexarotene, low dose MTX)
  • ECOG performance status 0-3
  • Life expectancy > 12 months
  • Female patients with childbearing potential must have a negative serum pregnancy test within two weeks of first dose of study drug. Male and female patients must agree to use an effective oral contraceptive method while on study treatment, if appropriate, and for a minimum of twelve months following study therapy

Exclusion Criteria:

  • Previously untreated patients
  • Presence of any organ or brain involvement as determined during tumor staging by contrast computed tomography [CT] or magnetic resonance imaging [MRI] scan
  • Known hereditary blood coagulation disorders/DIC
  • Prior allogeneic hematopoietic stem-cell or organ transplantation
  • Severe cardiovascular disease like functionally restricting heart rhythm disturbance or heart malformation or severe hypertension, or cardiac insufficiency > NHYA-II
  • known active infection including HIV, Hepatitis B or C, VZV, or CMV
  • Insufficient bone marrow reserve (Leucocytes <3.500/μl; Thrombocytes <100.000/μl)
  • Creatinine-Clearance < 50 ml/min or Crea > 1.8 mg/dl
  • Bilirubin > 2 mg/dl; ASAT, ALAT > 2.5xN
  • Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding
  • Known pulmonary dysfunction
  • Requirement of chronic immune suppression
  • Treatment with corticosteroids for concomitant or intercurrent disease
  • Having participated in another clinical trial or any IND in the preceding 4 weeks
  • Anti-cancer chemotherapy in the preceding 4 weeks
  • Known drug abuse/alcohol abuse
  • Known allergic/hypersensitivity reaction to any of the components of the treatment
  • Known serious uncontrolled infections
  • Known active secondary malignancy or other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the skin or cervix
  • Medical or psychological condition or inadequate knowledge of german language which in the opinion of the investigator would not permit the patient to complete the study or meaningfully sign informed consent
  • Legal incapacity or limited legal capacity
Both
18 Years to 70 Years
No
Contact: Michael Hoffmann, MD michael.hoffmann@uk-koeln.de
Germany
 
NCT01645293
Uni-Koeln-1065
Yes
Prof. Dr. med. Dr. rer. nat Cornelia Mauch, University of Cologne
University of Cologne
Not Provided
Not Provided
University of Cologne
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP